Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate

Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.